Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sufentanil + morphine is a combination of two potent opioid analgesics used for the management of severe pain, typically in clinical or perioperative settings. Both drugs act primarily as agonists at the mu-opioid receptor in the central nervous system, leading to profound analgesia and sedation. Sufentanil is a synthetic opioid that is significantly more potent than fentanyl and morphine, often used for anesthesia induction and maintenance or short-term acute pain control[2][8]. Morphine is a naturally derived opiate widely used for both acute and chronic severe pain management[6][10]. The combination may be considered when synergistic effects are desired or when titrating complex pain regimens under close medical supervision. Both agents carry risks of respiratory depression, dependence, tolerance, and other opioid-related adverse effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sufentanil + morphine.